An overview of the direct thrombin inhibitor argatroban

Pathophysiology of Haemostasis and Thrombosis

Volumn 32, Issue SUPPL. 3, 2002, Pages 9-14

  Walenga, Jeanine M ^a  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Anticoagulant; Argatroban; Thrombin inhibitor

Indexed keywords

ARGATROBAN; HEPARIN; HIRUDIN DERIVATIVE; HIRULOG; LEPIRUDIN; THROMBIN INHIBITOR; WARFARIN;

ANTICOAGULATION; CLINICAL TRIAL; DRUG ACTIVITY; DRUG BINDING; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DEGRADATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; DRUG MONITORING; DRUG PENETRATION; DRUG SAFETY; DRUG WITHDRAWAL; HIGH RISK PATIENT; HUMAN; HYPERCOAGULABILITY; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; REVIEW; STEADY STATE; STROKE; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTOPENIA; TRANSLUMINAL CORONARY ANGIOPLASTY;

HUMANS; PIPECOLIC ACIDS; THROMBIN; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT OUTCOME;

EID: 0344946475     PISSN: 14248832     EISSN: None     Source Type: Journal    
DOI: 10.1159/000069103     Document Type: Review

References (43)

1. Okamoto S, Hijikata A: Potent inhibition of thrombin by the newly synthesized arginine derivative No. 805. The importance of stereo-structure of its hydrophobic carboxamide portion. Biochem Biophys Res Commun 1981; 101:440-446.
2. Okamoto S, Hijikata-Okunomiya A: Synthetic selective inhibitors of thrombin. Methods Enzymol 1993;222:328-340.
3. Hursting MJ, Alford KL, Becker JC, Brooks RL, Joffrion JL, Knappenberger GD, Kogan PW, Kogan TP, McKinney AA, Schwarz RP: Novastan (brand of argatroban): A small-molecule, direct thrombin inhibitor. Semin Thromb Hemost 1997;23:503-516.
4. Jeske W, Walenga JM, Lewis BE, Fareed J: Pharmacology of argatroban. Exp Opin Invest Drugs 1999;8:625-654.
5. Bush LR: Argatroban, a selective, potent thrombin inhibitor. Cardiovasc Drug Rev 1991;9:247-263.
6. Hijikata-Okunomiya A, Okamoto S: A strategy for a rational approach to designing synthetic selective inhibitors. Semin Thromb Hemost 1992;18:135-149.
7. 2-[(3-methyl-1,2,3,4-tetrahy dro-8-quinolinyl)sulfonyl]-L-arginyl)]- 2-piperi-dinecarboxylic acid. Biochemistry 1984;23:85-90.
8. Banner DW, Hadvary P: Inhibitor binding to thrombin with x-ray crystallographic studies. Adv Exp Med Biol 1993;340:27-33.
9. Bauer M, Brandstetter H, Turk D, Sturzebekker J, Bode W: Crystallographic determination of thrombin complexes with small synthetic inhibitors as a starting point for the receptor-based design of antithrombotics. Semin Thromb Hemost 1993;19:352-360.
10. Tatsuno J, Komatsu T, Iida S: Pharmacokinetic studies of argatroban (MD-805): Protein binding and blood cell binding. Jap Pharmacol Ther 1986;14(suppl 5):243-249.
11. Berry CN, Girard D, Lochot S, Lecoffre C: Antithrombotic actions of argatroban in rat models of venous, mixed and arterial thrombosis, and its effects on the tail transection bleeding time. Br J Pharmacol 1994;113:1209-1214.
12. Berry CN, Girardot C, Lecoffre C, Lunven C: Effects of the synthetic thrombin inhibitor argatroban on fibrin- or clot-incorporated thrombin: Comparison with heparin and recombinant hirudin. Thromb Haemost 1994;72:381-386.
13. Hantgan RR, Jerome WG, Hursting MJ: No effect of clot age or thrombolysis on argatroban's inhibition of thrombin. Blood 1998;92: 2064-2074.
14. Swan SK, Hursting MJ: The pharmacokinetics and pharmacodynamics of argatroban: Effects of age, gender, and hepatic or renal dysfunction. Pharmacotherapy 2000;20:318-329.
15. Swan SK, St. Peter JV, Lambrecht LJ, Hursting MJ: Comparison of anticoagulant effects and safety of argatroban and heparin in healthy subjects. Pharmacotherapy 2000;20:756-770.
16. Hursting MJ, Joffrion JL, Brooks RL, Swan SK: Effect of renal function on the pharmacoki-netics and pharmacodynamics of argatroban (a direct thrombin inhibitor). Blood 1996; 88(suppl 1):167a.
17. Hursting MJ, Becker JC, Joffrion JL, Knappenberger GD, Schwarz RP: Effect of hepatic function on the pharmacokinetics and pharmacodynamics of argatroban. Thromb Haemost 1997(suppl);493-494.
18. Izawa O, Katsuki M, Komatsu T, Iida S: Pharmacokinetics studies of argatroban (MD-805) in human - Concentrations of argatroban and its metabolites in plasma, urine and feces during and after drip intravenous infusion (in Japanese). Jpn Pharmacol Ther 1986;14(suppl 5):251-263.
19. Ahmad S, Ahsan A, George M, Iqbal O, Jeske WP, McKenna R, Lewis BE, Walenga JM, Fareed J: Simultaneous monitoring of argatroban and its major metabolite using an HPLC method: Potential clinical applications. Clin Appl Thromb/Hemost 1999;5:252-258.
20. Walenga JM, Ahmad S, Hoppensteadt D, Iqbal O, Hursting MJ, Lewis BE: Argatroban therapy does not generate antibodies that alter its anticoagulant activity in patients with HIT. Thromb Res 2002;105:401-405.
21. Clark RJ, Mayo G, Fitzgerald GA, Fitzgerald DJ: Combined administration of aspirin and a specific thrombin inhibitor in man. Circulation 1991;83:1510-1518.
22. Tran JQ, DiCicco RA, Sheth SB: Assessment of the potential pharmacokinetic and pharmacodynamic interactions between erythromycin and argatroban. J Clin Pharmacol 1999;39: 513-519.
23. Inglis AL, Sheth SB, Hursting MJ, Tenero DM, Graham AM, DiCicco RA: Investigation of interaction between argatroban and acetamin-ophen, lidocaine, or digoxin. Am J Health Syst Pharm 2002;59:1258-1266.
24. Walenga JM, Fasanella AR, Iqbal O, Hoppensteadt DA, Ahmad S, Wallis DE, Bakhos M: Coagulation laboratory testing in patients treated with argatroban. Semin Thromb Hemost 1999;25(suppl 1):61-66.
25. Sheth SB, DiCicco RA, Hursting MJ, Montague T, Jorkasky DK: Interpreting the International Normalized Ratio in individuals receiving argatroban and warfarin. Thromb Haemost 2001;85:435-440.
26. Hursting MJ, Zehnder JL, Joffrion JL, Becker JC, Knappenberger GD, Schwarz RP: The International Normalized Ratio during concurrent warfarin and argatroban anticoagulation: Differential contributions of each agent and effects of the choice of thromboplastin used. Clin Chem 1999;45,409-412.
27. Lewis BE, Ferguson JJ, Grassman ED, Fareed J, Walenga JM, Joffrion JL, Wrona L, Johnson SA, Schwarz RP, McKiernan T: Successful coronary interventions performed with argatroban anticoagulation in patients with heparin-induced thrombocytopenia and thrombosis syndrome. J Invas Cardiol 1996;8:410-417.
28. Lewis BE, Wallis DE, Berkowitz SD, Matthai WH, Fareed J, Walenga JM, Bartholomew J for the ARG-911 Study Investigators: Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation 2001; 103:1838-1843.
29. Lewis BE, Wallis DE, Zehnder JL, Barton JC, for the ARG-911/915/915X investigators: Argatroban reexposure in patients with HIT. Blood 2000;96(pt 1):52a.
30. Lewis BE, Matthai WH Jr, Cohen M, Moses JW, Hursting MJ, Leya F, ARG-216/310/311 Study Investigators: Argatroban anticoagulation during percutaneous coronary intervention in patients with heparin-induced thrombocytopenia. Catheter Cardiovasc Interv 2002; 57:177-184.
31. Itoh T, Nonogi H, Miyazaki S, Itoli A, Daikoko S: Local delivery of argatroban using drug delivery device 'dispatch' in the prevention of restenosis following coronary angioplasty trial (40-CAT): Result of the prospective randomized pilot study. Circulation 1997;96:3635.
32. Kobayashi H, Suzuki S, Sakamoto S, Matsuo T: Argatroban, a direct thrombin inhibitor versus heparin during and after percutaneous transluminal coronary angioplasty (PTCA). Thromb Haemost 1997(suppl);494.
33. Herrman J-P, Suryapranata H, den Heijer P, Gabriël L, Kutryk MJB, Serruys PW: Argatroban during percutaneous transluminal coronary angioplasty: Results of a dose-verification study. J Thromb Thrombolysis 1996;3:367-375.
34. Lewis BE, Rangel Y, Fareed J: The first report of successful carotid stent implant using argatroban anticoagulation in a patient with heparin-induced thrombocytopenia and thrombosis syndrome. Angiology 1998;49:61-67.
35. Lewis BE, Grassman ED, Wrona L, Rangel Y: Novastan anticoagulation during renal stent implant in a patient with HIT. Blood Coagul Fibrinolysis 1997;8:54-58.
36. Kobayashi S, Tazaki Y: Effect of the thrombin inhibitor argatroban in acute cerebral thrombosis. Sem Thromb Hemost 1997;23:531-534.
37. Gold HK, Torres FW, Garabedian HD, Werner W, Jang IK, Khan A, Hagstrom JN, for the study investigators: Evidence for a rebound coagulation phenomenon after cessation of a 4-hour infusion of a specific thrombin inhibitor in patients with unstable angina pectoris. J Am Coll Cardiol 1993;21:1039-1047.
38. Matsuo T, Kario K, Matsuda S, Yamaguchi N, Kakishita E: Effect of thrombin inhibition on patients with peripheral arterial obstructive disease: A multicenter clinical trial of argatroban. J Thromb Thrombolysis 1995;2:131-136.
39. Jang I-K, Brown DF, Giugliano RP, Anderson HV, Losordo D, Nicolau JC, Dutra OP and the MINT investigators: A multicenter, randomized study of argatroban versus heparin as adjunct to TPA in acute myocardial infarction: Myocardial infarction with Novastan and TPA (MINT) trial. J Am Coll Cardiol 1999;33: 1879-1885.
40. Vermeer F, Vahanian A, Fels P, Besse P, Muller E, van de Werf F, Fitzgerald D, Darius H, Puel J, Garrigou D, Simoons ML: Argatroban and alteplase in patients with acute myocardial infarction: The ARGAMI study. J Thromb Thrombolysis 2000;10:233-240.
41. Matsuo T, Chikahira Y, Yamada T, Nakao K, Ueshima S, Matsuo O: Effect of synthetic thrombin inhibitor (MD805) as an alternative drug on HIT during hemodialysis. Thromb Res 1988;52:165-171.
42. Koide M, Yamamoto S, Matsuo M, Suzuki S, Arima N, Matsuo T: Anticoagulation for HIT with spontaneous platelet aggregation in a patient requiring haemodialysis. Nephrol Dial Transplant 1995;10:2137-2140.
43. Eichler P, Friesen H-J, Lubenow N, Jaeger B, Greinacher A: Antihirudin antibodies in patients with HIT treated with lepirudin: Incidence, effects on aPTT, and clinical relevance. Blood 2000;96:2373-2378.